{"schema_version":"1","generated_at":"2026-10-28T04:20:04.536Z","data_as_of":"2026-10-23","url":"https://www.findmykol.com/kol/ryan-cassaday","json_url":"https://www.findmykol.com/kol/ryan-cassaday/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"ryan-cassaday","name":"Ryan Cassaday","credential":"MD","title":"Professor, Division of Hematology and Oncology, University of Washington","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Leukemia","therapeutic_areas":["Leukemia","Lymphoma"],"institution":"University of Washington","institution_url":"https://www.findmykol.com/institution/university-of-washington","city":"Seattle","state":"WA","region":{"label":"West","url":"https://www.findmykol.com/region/west"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1508060583","orcid":"0000-0002-3424-2425","openalex":"A5071844603"},"summary":"Ryan Cassaday is Professor, Division of Hematology and Oncology, University of Washington at University of Washington. OpenAlex indexes 343 publications with 7,332 citations (h-index 39); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.","overview":{"text":"Ryan Cassaday, M.D., is Professor, Division of Hematology and Oncology, University of Washington. The public record shows 343 publications with 7,332 citations (h-index 39), centered on CAR-T cell therapy research, Acute Lymphoblastic Leukemia research, Lymphoma Diagnosis and Treatment. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 11 companies.","bullets":["Most recent indexed publication: 2026 · Blood advances","Top research focus: CAR-T cell therapy research","8 registered trials on ClinicalTrials.gov","Open Payments reporting from 11 companies"],"generated_at":"2026-10-27"},"focus":{"indications":[{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":8,"topics":2,"strength":26},{"label":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","therapeutic_area":"Oncology","trials":8,"topics":0,"strength":24},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":5,"topics":1,"strength":16},{"label":"Philadelphia Chromosome","therapeutic_area":"Epidemiology","trials":2,"topics":0,"strength":6},{"label":"Neoplasm, Residual","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["CAR-T cell therapy research","Acute Lymphoblastic Leukemia research","Lymphoma Diagnosis and Treatment","Chronic Lymphocytic Leukemia Research","Hematopoietic Stem Cell Transplantation"],"drugs_studied":{"total":9,"shown":3,"withheld":6,"rows":[{"name":"Tecartus","generic":"Brexucabtagene autoleucel","trials":0,"payments":13,"publications":7,"mentions":20},{"name":"Besponsa","generic":"Inotuzumab ozogamicin","trials":0,"payments":5,"publications":9,"mentions":14},{"name":"Blincyto","generic":"Blinatumomab","trials":0,"payments":8,"publications":2,"mentions":10}]},"works_with":{"total":13,"shown":3,"withheld":10,"rows":[{"name":"Kite Pharma, Inc.","trials":0,"payments":13,"mentions":13},{"name":"Amgen Inc.","trials":0,"payments":11,"mentions":11},{"name":"Jazz Pharmaceuticals Inc.","trials":0,"payments":7,"mentions":7}]}},"scholarship":{"works_count":343,"cited_by_count":7332,"h_index":39,"i10_index":89,"pubmed_count":34,"latest_activity_year":2026,"source":"works"},"trials":{"count":8,"shown":3,"withheld":5,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07224100","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"University of Washington","source_url":"https://clinicaltrials.gov/study/NCT07224100","trial_url":"https://www.findmykol.com/trial/NCT07224100"},{"nct":"NCT06738368","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"University of Washington","source_url":"https://clinicaltrials.gov/study/NCT06738368","trial_url":"https://www.findmykol.com/trial/NCT06738368"},{"nct":"NCT05453500","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Investigator","sponsor":"University of Washington","source_url":"https://clinicaltrials.gov/study/NCT05453500","trial_url":"https://www.findmykol.com/trial/NCT05453500"}],"source":"trials"},"payments":{"company_count":11,"program_years":{"first":2021,"last":2025},"rows_total":22,"shown":3,"withheld":19,"rows":[{"payer":"Autolus Inc","program_year":2025,"amount_usd":5391.04,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1508060583"},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":3700,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1508060583"},{"payer":"SERVIER PHARMACEUTICALS LLC","program_year":2025,"amount_usd":2800,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1508060583"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1508060583","source":"payments"},"prescribing":{"data_year":2024,"areas_total":2,"areas_shown":2,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":71.4,"classes_total":2,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":42.9,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":null},{"class":"Bile Acid","setting":"prescribed","share_pct":28.6,"drugs":[{"name":"Ursodiol","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":28.6,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":28.6,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"congress":{"count":103,"years":{"first":2006,"last":2026},"societies":["AACR","ASCO","ASH","ASTRO","ESMO"],"shown":3,"withheld":100,"rows":[{"title":"Phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) in adults with newly diagnosed (ND) Philadelphia chromosome–negative (Ph-) B lymphoblastic leukemia (B-ALL).","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.6535","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6535","status":"verified"},{"title":"Preliminary results of an open-label, single-arm phase 2/3 trial (SPARK-ALL) of calaspargase pegol in adults with newly diagnosed Philadelphia chromosome–negative acute lymphoblastic leukemia.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.6529","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.6529","status":"verified"},{"title":"Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL).","society":"ASCO","meeting":"ASCO Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.6540","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.6540","status":"verified"}],"source":"congress"},"publications":{"total":34,"shown":5,"withheld":29,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Incidence and risk factors for CNS relapse in adult ALL after allogeneic hematopoietic cell transplantation.","year":2026,"journal":"Blood advances","types":["Journal Article","Multicenter Study"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42348785/","status":"verified"},{"title":"Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.","year":2026,"journal":"Blood advances","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42349018/","status":"verified"},{"title":"Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.","year":2026,"journal":"Leukemia & lymphoma","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42611806/","status":"verified"},{"title":"Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.","year":2026,"journal":"Blood","types":["Journal Article","Consensus Statement"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42154904/","status":"verified"},{"title":"Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.","year":2026,"journal":"Blood","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41643192/","status":"verified"}],"most_cited":{"total":343,"shown":5,"withheld":338,"rows":[{"title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","year":2021,"cited_by_count":822,"type":"article","source_url":"https://doi.org/10.1016/s0140-6736(21)01222-8"},{"title":"The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis","year":2004,"cited_by_count":706,"type":"article","source_url":"https://doi.org/10.1038/nm982"},{"title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","year":2014,"cited_by_count":467,"type":"article","source_url":"https://doi.org/10.1182/blood-2014-05-578963"},{"title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","year":2019,"cited_by_count":404,"type":"article","source_url":"https://doi.org/10.1182/blood-2018-11-883710"},{"title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","year":2019,"cited_by_count":354,"type":"article","source_url":"https://doi.org/10.1182/blood-2018-11-887067"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Brian G. Till","coauthored_works":96,"profile_url":"https://www.findmykol.com/kol/brian-till-us"},{"name":"Ajay K. Gopal","coauthored_works":95},{"name":"Mazyar S. Shadman","coauthored_works":90}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/ryan-cassaday-md","status":"verified"}]},"mentions":{"total":1,"shown":1,"rows":[{"url":"https://www.fredhutch.org/en/faculty-lab-directory/cassaday-ryan.html","platform":"other","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":1,"shown":1,"rows":[{"value":"MD, University of Wisconsin School of Medicine and Public Health","source_url":"https://www.fredhutch.org/en/provider-directory/ryan-d-cassaday.html","status":"verified","collected_at":"2026-10-26"}]},"roles":{"total":1,"shown":1,"rows":[{"value":"Member, NCCN Guidelines Panel for Acute Lymphoblastic Leukemia","source_url":"https://education.binaytara.org/node/2149/bio/6719/view","status":"provisional","collected_at":"2026-10-26"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"Professor, Clinical Research Division, Fred Hutch Cancer Center","source_url":"https://hemonc.uw.edu/people/ryan-cassaday","status":"verified","collected_at":"2026-10-26"}]},"media":{"total":1,"shown":1,"rows":[{"value":"Oncology Insights with Dr. Petros Grivas, Episode 19 (Fred Hutch, August 2026): discussion of recent advances in acute lymphoblastic leukemia treatment","source_url":"https://www.fredhutch.org/en/news/center-news/2026/08/oncology-insights-ryan-cassaday-petros-grivas-episode-19.html","status":"verified","collected_at":"2026-10-26"}]}},"similar":[{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Connie Celum","slug":"connie-celum","institution":"University of Washington","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/connie-celum","json_url":"https://www.findmykol.com/kol/connie-celum/profile.json"},{"name":"Helen Chu","slug":"helen-chu","institution":"University of Washington","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/helen-chu","json_url":"https://www.findmykol.com/kol/helen-chu/profile.json"},{"name":"Bryan Kestenbaum","slug":"bryan-kestenbaum","institution":"University of Washington","specialty":"Nephrology","url":"https://www.findmykol.com/kol/bryan-kestenbaum","json_url":"https://www.findmykol.com/kol/bryan-kestenbaum/profile.json"},{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Jorge Cortes","slug":"jorge-cortes","institution":"University of Alabama at Birmingham (UAB)","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/jorge-cortes","json_url":"https://www.findmykol.com/kol/jorge-cortes/profile.json"},{"name":"Ayalew Tefferi","slug":"ayalew-tefferi","institution":"Mayo Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/ayalew-tefferi","json_url":"https://www.findmykol.com/kol/ayalew-tefferi/profile.json"},{"name":"Charles Sawyers","slug":"charles-sawyers","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/charles-sawyers","json_url":"https://www.findmykol.com/kol/charles-sawyers/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":5,"payments":19,"congress":100,"publications":29,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-26"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-26"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-10-26"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-26"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-26"}},"methodology_url":"https://www.findmykol.com/about#methodology"}